Specific Biologics Raises US$35 Million for ALS Research Programme

On 2 November 2026, Canadian biotechnology company Specific Biologics announced a US$35 million Series A financing round led by Hatteras Venture Partners. The funding will advance its Dualase programme towards an initial biomarker proof-of-concept in a clinical trial for C9ORF72-associated ALS, creating opportunities for biotechnology research and specialist healthcare partnerships. HPC can support medical research organisations with biomedical data analytics, AI-assisted research, clinical-data processing and secure health-information infrastructure.